Search for grants with us!
Grants you might be eligible for
Modular R01s in Cancer Control and Population Sciences
PA-25-172
Programme: NIH Research Project Grant
General Overview
Organizational Aspects
Funding
Up to 250000.00 USD
Deadline
Oct. 5, 2027, 10 p.m.
Innovative Programs to Enhance Research Training (IPERT)
PAR-24-252
Programme: NIH Research Education Program (R25)
Up to 500000.00 USD
Oct. 15, 2026, 10 p.m.
IDeA Clinical and Translational Research Development (CTR-D) Award
PAR-23-257
Programme: IDeA Program
Up to 100000.00 USD
Oct. 9, 2025, 5 p.m.
Clinical Coordinating Center for NCCIH Multi-Site Investigator-Initiated Clinical Trials of Natural Products
PAR-24-123
Programme: NIH Grants
Up to None USD
July 14, 2026, 10 p.m.
NCI Research Specialist (Clinician Scientist) Award (R50)
PAR-24-274
Programme: NCI Research Specialist Award
Nov. 5, 2025, 10 p.m.
Personal Health Informatics for Delivering Actionable Insights to Individuals (R01 Clinical Trial Optional)
PAR-25-235
Programme: NIH Research Project Grants
GRANT OVERVIEW
ELIGIBILITY CRITERIA
Jan. 7, 2027, 10 p.m.
Accelerating the Pace of Substance Use Research Using Existing Data
RFA-DA-26-056
Up to 275000.00 USD
Dec. 3, 2025, 10 p.m.
Cellular and Molecular Biology of Complex Brain Disorders (R21 Clinical Trial Not Allowed)
PAR-25-037
Up to 200000.00 USD
June 16, 2026, 10 p.m.
Innovation Grants to Nurture Initial Translational Efforts (IGNITE)
PAR-25-060
Programme: NIH IGNITE Program
Up to 499000.00 USD
Oct. 20, 2027, 10 p.m.
Functional Validation and/or Characterization of Genes or Variants Implicated in Substance Use Disorders
PAR-24-267
July 28, 2025, 10 p.m.
Bidirectional Influences Between Adolescent Social Media Use and Mental Health (R21 Clinical Trial Optional)
RFA-MH-25-206
Oct. 20, 2025, 10 p.m.
Early Stage Testing of Pharmacologic or Neuromodulatory Device-based Interventions for the Treatment of Mental Disorders
PAR-25-184
Programme: National Institutes of Health (NIH)
Feb. 17, 2027, 10 p.m.
Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required)
PAR-25-226
Nov. 19, 2026, 10 p.m.
Clinical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U01 Clinical Trial Optional)
PAR-25-055
June 22, 2026, 10 p.m.
NIA Multi-site Clinical Trial Implementation Grant
PAR-25-222
June 5, 2025, 10 p.m.
Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes
PAR-25-096
June 16, 2025, 10 p.m.
Pilot Effectiveness Trials for Post-Acute Interventions and Services to Optimize Longer-term Outcomes
PAR-25-206
Up to 750000.00 USD
Novel Mechanism Research on Neuropsychiatric Symptoms in Alzheimer's Dementia
PAR-25-064
NIDDK Central Repository Non-renewable Sample Access
PAR-22-171
Programme: NIH Resource Access Award
June 27, 2025, 5 p.m.
Prevention and Intervention Approaches for Fetal Alcohol Spectrum Disorders (R61/R33 Clinical Trial Optional)
PAR-25-158
Nov. 18, 2026, 10 p.m.
543 results. Page 7 of 28.